Skip to main content
Premium Trial:

Request an Annual Quote

Biotage s Aims to Begin Employee Stock Option Program

NEW YORK, March 23 (GenomeWeb News) - Biotage's board of directors may soon establish an employee stock option program after its April 27 meeting, the company said today in a statement.


If voting during the company's general meeting authorizes the board to make the changes, the total number of shares will not exceed 8.8 million, the firm said. Like other companies, Biotage issues new shares to help finance acquisitions or to strengthen its capital base and its equity holdings, the company added.


The board's plan for a stock option program will allow employees to be allocated no more than a combined total of 600,000 options until next year's general meeting. Management may be allocated as many as 80,000 options each, senior executives can receive a maximum of 30,000 options each, junior executives can each receive as many as 10,000 options, while other executives can receive a maximum of 3,600 each, the company said.


Other employees can receive a maximum of 400 options each.


The company will issue no more than 700,000 warrants, which if fully exercised will result in a market capitalization increase of 700,000 Swedish Kronor ($90,300), Biotage said. That amount corresponds to a dilution of less than one percent of the share capital and votes, the company added.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.